Navigation Links
IVI granted 2 US patents on dysentery vaccine inventions

SEOUL, KOREA The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide. This infectious disease, caused by the bacterial pathogen Shigella, is a major health problem in developing countries, as young children are particularly vulnerable to the disease. The United States Patent and Trademark Office recently issued two patents on "Novel Shigella protein antigens and methods" to IVI. These two patents will accelerate the Institute's current efforts in developing an effective and low-cost vaccine for use among impoverished communities afflicted by dysentery.

The Shigella vaccine patents, which will expire in 2029, are the most recently issued patents of IVI. IVI filed these two patents (Applications No. 12/603,574 and No. 12/692,187) following its discovery of novel common protein antigens in several Shigella species that could be used as the basis of a universal vaccine against bacillary dysentery. With the potential to provide cross-protection across species and serotypes of Shigella, this could be the first broadly protective vaccine against dysentery. The patents claim vaccine compositions comprising either of two novel conserved Shigella proteins and a conjugate molecule comprising an O-specific polysaccharide antigen of Shigella bacteria covalently bound to either of these Shigella proteins.

Dr. Cecil Czerkinsky, IVI's Deputy Director-General of Laboratory Sciences and Dr. Dong Wook Kim, Associate Professor at Hanyang University and former IVI scientist, reported the original discovery of the Shigella common protein antigens in a provisional patent application filed in October 2008. Dr. Czerkinsky commented, "We are extremely excited about the issuance of the Shigella vaccine patents. It further reinforces our belief that these common proteins, through their immunological properties, may be highly effective in preventing shigellosis, a diarrheal disease that claims countless lives of children every year, mainly in developing countries."

"This patent issuance is an important milestone on IVI's path of delivering a new vaccine against another killer infectious disease," added Dr. Christian Loucq, IVI's Director-General. "Furthermore, it underlies the dynamism and productivity of IVI scientists."


Contact: Tae Kyung Byun
International Vaccine Institute

Related biology news :

1. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
2. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. Company Granted Patent on Apparatus, Systems, and Methods for Gathering and Processing Wireless Biometric and Biomechanical Data
4. BIO-key(R) Granted Patent for Trusted Biometric Device Security Solution
5. 2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
6. BIO-key(R) Granted Patent to Secure Biometric Enrollments From Unauthorized Use
7. BIO-key(R) Granted Additional Patent for Biometric Security Solution
8. U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents
9. US Patent Office affirms Zamore Design Rule patents
10. Digital data forensic expert at NJIT to be feted by R&D council for data hiding patents
11. IEEE-USA pleased that Supreme Courts ruling preserves software patents
Post Your Comments:
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/27/2015)... Calif. , Oct. 27, 2015 Synaptics Inc. ... solutions, today announced that Google has adopted the Synaptics ... touch controller solutions to power its newest flagship smartphones, ... by Huawei. --> ... like Google to provide strategic collaboration in the joint ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
Breaking Biology Technology: